<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61283">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308124</url>
  </required_header>
  <id_info>
    <org_study_id>1409066609</org_study_id>
    <nct_id>NCT02308124</nct_id>
  </id_info>
  <brief_title>Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study</brief_title>
  <official_title>Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the effect of treatment of midodrine and pyridostigmine in neurogenic orthostatic
      hypotension and investigate the quality of life of treatment of neurogenic orthostatic
      hypotension.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalization of orthostatic bood pressure (BP) - heart rate (HR) test</measure>
    <time_frame>after 3-month medical treatment</time_frame>
    <description>Normalization of orthostatic BP-HR test after 3-month medical treatment compared to initial results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the subjective symptom survey result</measure>
    <time_frame>after 3-month medical treatment.</time_frame>
    <description>Change of the subjective symptom survey result after 3-month medical treatment compared to initial results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the QOL</measure>
    <time_frame>after 3-month medical treatment.</time_frame>
    <description>Change of the QOL after 3-month medical treatment after 3-month medical treatment compared to initial results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the depression score</measure>
    <time_frame>after 3-month medical treatment.</time_frame>
    <description>Change of the depression score after 3-month medical treatment compared to initial results.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Orthostatic; Hypotension, Neurogenic</condition>
  <arm_group>
    <arm_group_label>Midodrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if tolerable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyridostigmine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if tolerable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midodrine + Pyridostigmine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if tolerable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <arm_group_label>Midodrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridostigmine Bromide</intervention_name>
    <arm_group_label>Pyridostigmine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine + pyridostigmine bromide</intervention_name>
    <arm_group_label>Midodrine + Pyridostigmine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;=18 patients who complained of dizziness

          -  Orthostatic hypotension after 3-minute standing (systolic blood pressure drop &gt;=20 or
             diastolic blood pressure drop &gt;=10

        Exclusion Criteria:

          -  Drug-induced hypotension, if necessary, evaluate patient after discontinuing the
             causative drug for one month

          -  Heart failure or Chronic renal failure

          -  Patients who cannot or do not want to write questionaires.

          -  Poor drug compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kon Chu, Professor</last_name>
    <email>stemcell.snu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jung-Ik Byun, Fellow</last_name>
    <email>mr830611@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kon Chu, Professor</last_name>
      <email>stemcell.snu@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jung-Ik Byun, Fellow</last_name>
      <email>mr830611@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kon Chu, MD, PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Arbique D, Cheek D, Welliver M, Vongpatanasin W. Management of neurogenic orthostatic hypotension. J Am Med Dir Assoc. 2014 Apr;15(4):234-9. doi: 10.1016/j.jamda.2013.10.014. Epub 2014 Jan 2. Review.</citation>
    <PMID>24388946</PMID>
  </reference>
  <reference>
    <citation>Smith ND. Orthostatic Hypotension in the Patient with Diabetes: A Broad Review of Pharmacologic Treatment Options. Journal of Pharmacy Technology. 2013 January 1, 2013;29(1):23-34.</citation>
  </reference>
  <reference>
    <citation>Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol. 2008 May;7(5):451-8. doi: 10.1016/S1474-4422(08)70088-7. Review.</citation>
    <PMID>18420158</PMID>
  </reference>
  <reference>
    <citation>Shibao C, Grijalva CG, Raj SR, Biaggioni I, Griffin MR. Orthostatic hypotension-related hospitalizations in the United States. Am J Med. 2007 Nov;120(11):975-80.</citation>
    <PMID>17976425</PMID>
  </reference>
  <reference>
    <citation>Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009 Jan 6;119(1):139-46. doi: 10.1161/CIRCULATIONAHA.108.805887. Review.</citation>
    <PMID>19124673</PMID>
  </reference>
  <reference>
    <citation>Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006 Sep;13(9):930-6.</citation>
    <PMID>16930356</PMID>
  </reference>
  <reference>
    <citation>Parsaik AK, Singh B, Altayar O, Mascarenhas SS, Singh SK, Erwin PJ, Murad MH. Midodrine for orthostatic hypotension: a systematic review and meta-analysis of clinical trials. J Gen Intern Med. 2013 Nov;28(11):1496-503. doi: 10.1007/s11606-013-2520-3. Epub 2013 Jun 18. Review.</citation>
    <PMID>23775146</PMID>
  </reference>
  <reference>
    <citation>Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, Low PA. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998 Jul;51(1):120-4.</citation>
    <PMID>9674789</PMID>
  </reference>
  <reference>
    <citation>Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012 Apr;22(2):79-90. doi: 10.1007/s10286-011-0146-2. Epub 2011 Nov 2.</citation>
    <PMID>22045363</PMID>
  </reference>
  <reference>
    <citation>Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993 Jul;95(1):38-48.</citation>
    <PMID>7687093</PMID>
  </reference>
  <reference>
    <citation>Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997 Apr 2;277(13):1046-51. Erratum in: JAMA 1997 Aug 6;278(5):388.</citation>
    <PMID>9091692</PMID>
  </reference>
  <reference>
    <citation>Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1294-8.</citation>
    <PMID>12933939</PMID>
  </reference>
  <reference>
    <citation>Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines S, O'Brien PC, Slezak J, Low PA. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006 Apr;63(4):513-8. Epub 2006 Feb 13.</citation>
    <PMID>16476804</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 15, 2015</lastchanged_date>
  <firstreceived_date>December 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Kon Chu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Pyridostigmine Bromide</mesh_term>
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
